NextFin News - A multidisciplinary research team at the Wyss Institute at Harvard University and the Dana-Farber Cancer Institute has unveiled a nanostructured vaccine platform that could fundamentally alter the global response to rapidly mutating viruses. The technology, dubbed DoriVac, utilizes DNA origami to achieve molecular-level precision in vaccine composition, successfully inducing broad immunity against SARS-CoV-2, HIV, and Ebola in preclinical models. Published today in Nature Biomedical Engineering, the findings arrive as the limitations of first-generation mRNA vaccines—specifically their waning durability and vulnerability to viral evolution—have become a central challenge for public health policy under U.S. President Trump’s administration.
The DoriVac platform represents a departure from the lipid nanoparticle (LNP) delivery systems used by Pfizer and Moderna. Instead of a fatty envelope, DoriVac uses self-assembling DNA "blocks" that act as a programmable chassis. On one face, the structure presents adjuvant molecules with nanometer-scale spacing optimized to trigger dendritic cells; on the opposite face, it carries highly conserved antigens. By targeting the HR2 peptide region—a segment of the viral spike protein that remains nearly identical across variants—the vaccine bypasses the "arms race" of the receptor-binding domain where most mutations occur. In mice, the SARS-CoV-2 HR2 vaccine produced significantly greater activation of both humoral antibody-producing B cells and cellular CD8+ T cells compared to traditional vaccine components.
The economic and logistical implications of this shift are substantial. While mRNA-LNP vaccines saved millions of lives, they remain tethered to a complex "cold chain" and expensive manufacturing processes. DoriVac structures are inherently more stable, potentially eliminating the need for ultra-low-temperature storage that has hampered vaccine distribution in developing economies. Furthermore, the precision of DNA origami allows for a level of quality control that is difficult to achieve with LNPs, where the number of mRNA molecules per particle can vary. This modularity means the platform can be "reprogrammed" for new pathogens by simply swapping the antigen face, offering a blueprint for rapid-response biodefense.
To bridge the gap between animal models and human outcomes, the researchers utilized the Wyss Institute’s "human lymph node-on-a-chip" technology. This microfluidic system, which mimics human immune responses in vitro, confirmed that the DoriVac platform activates human dendritic cells and protective T cells at levels comparable to or exceeding current mRNA standards. In head-to-head mouse trials using a common booster protocol, DoriVac elicited anti-viral T cell and B cell responses that matched the performance of the Moderna and Pfizer/BioNTech vaccines, but with the added benefit of targeting conserved regions that are less likely to be rendered obsolete by the next variant of concern.
The transition from laboratory breakthrough to clinical reality is now being led by DoriNano, a startup co-founded by lead researcher Yang (Claire) Zeng. As the biotechnology sector looks for "mRNA-plus" solutions, the ability to program immune recognition at the molecular level offers a path toward vaccines that are not only more durable but also more equitable in their global reach. The success of this DNA nanotechnology suggests that the future of immunization may lie not in the chemistry of lipids, but in the structural engineering of genetic material itself.
Explore more exclusive insights at nextfin.ai.
